FREQUENTLY ASKED QUESTIONS
Given that the death of some pregnant animals is unavoidable, the fetus can be used to serve science, and generate jobs. This contribution benefits research and development and should not be underestimated.
The collection of the blood is done without causing pain to the fetus. The fetus’s life ends through oxygen depletion, generally agreed to be a gentle method of life termination. Cell culture technology can reduce the use of live animals in science. Research is also being done to produce meat by cell culture, which could ultimately lead to the end of breeding animals for food.
The slaughtering of pregnant animals is, in most cases, an unplanned event. The frequency depends on farming techniques. In most cases, the condition of gestation is unknown; especially where animals are produced naturally; in the case of cattle moving freely around, grass fed, heifers and steers together. No cows are killed with the main purpose of harvesting the fetal blood. The blood is collected as a by-product from cattle slaughter operations for the bovine meat. The pregnancy condition is unknown when an animal enters the slaughtering line. The percentage of pregnant cows going to slaughter is very low and decreasing year by year as cattle farming techniques constantly improve.
The OIE (World Organization for Animal Health) is an intergovernmental organization created in 1924. In 2011, the OIE totaled 178 Member Countries and Territories.
Its missions are:
- To ensure transparency in the global animal disease situation
- To collect, analyze and disseminate veterinary scientific information
- To provide expertise and encourage international solidarity in the control of animal diseases
- To safeguard world trade by publishing health standards for international trade in animals and animal products
- To improve the legal framework and resources of National Veterinary Services Organization.
Fetal Bovine Serum
There are some cell lines specific serum-free alternatives available. In most cases, cell adaptation is needed, yields are lower and costs are higher.
FBS is essentially a natural product. All FBS batches are unique, with specific characteristics, different from all other batches.
The demand for FBS is growing along with the latest research developments, including stem cells, cell therapy, new vaccines and proteomics.
The availability of FBS is diminishing. Meat and calf prices are increasing as consumers in some countries increase the consumption of beef; and as cattle breeding techniques are permanently improving. These combined factors lead to a reduced frequency of pregnant cows at slaughter. The collection of FBS in new countries has, for many years, compensated for the decrease in supply; but now there are no more new producer countries available. The present world supply of FBS is short and will continue decreasing.
FBS Imports into the EU are less restricted than in the USA. A proposal made by USDA in 1994 to apply the same FBS import policies as the EU did not get support from the US FBS industry. The International Serum Industry Association (ISIA) supports efforts to harmonize import rules, suggesting compliance with the OIE recommendations. In the meantime, FBS in the USA remains more than twice as expensive as in Europe.
The serum’s origin has no influence on cell growth. Biosera has compared cell growth in FBS from seven different countries on three continents, and confirmed that regardless of the country of origin, all cell lines tested had the same average performance. One batch of FBS may work well for one specific cell line, but not for another. “Serum quality” is specific for each cell line. That is why testing of FBS is widely used when dealing with sensitive cell lines. Biosera performs the most extensive analysis of biochemical parameters and testing on cell lines in the industry, making available the results on the Certificates of Analysis.
A huge price difference exists between countries classified as “FMD-Free-without-vaccination” for which demand exceeds supply, and countries listed as “FMD-Free-with-vaccination” where supply historically has exceeded demand. The price difference has been several hundred per cent, whereby serum users in the US have paid billions of USD more than serum users in the EU. Proposals from USDA to harmonize US and EU import rules for FBS relating to FMD (following OIE guidelines), have repeatedly been turned down by the US serum industry.
Wrong beliefs about risks associated to BSE have lead some FBS providers to promote the Australian origin as “safer” without any scientific basis, making this origin several times more expensive than any other. The Australia “safer” status is being promoted, despite the virus status of Australia; and despite the higher risk of misrepresentation associated with such huge price differences.
The price differences persist due to longtime marketing efforts promoting certain origins, and regulations limiting trade, even among countries that according to the OIE’s classification have identical veterinary risk status (regarding viruses of import concern for FBS). ISIA has among its objectives the education of serum users, and EU and USA are working to harmonize trade rules, all of which will contribute to harmonizing price levels for most FBS origins.
Il existe une importante différence de prix entre les pays classés dans la catégorie “exempt de fièvre aphteuse sans vaccination” pour lesquels la demande dépasse l’offre, et les pays répertoriés dans la catégorie “exempts de fièvre aphteuse avec vaccination”, où l’offre a toujours dépassé la demande. La différence de prix a été de plusieurs centaines de pour cent, les utilisateurs de sérum aux États-Unis ayant payé des milliards de dollars de plus que les utilisateurs de sérum dans l’UE. Les propositions de l’USDA visant à harmoniser les règles d’importation des États-Unis et de l’Union européenne en matière de SVF relatives à la fièvre aphteuse (conformément aux directives de l’OIE) ont été maintes fois rejetées par l’industrie américaine du sérum. De fausses croyances sur les risques associés à l’ESB ont conduit certains fournisseurs de SVF à promouvoir l’origine australienne comme “plus sûre” sans fondement scientifique, rendant cette origine plusieurs fois plus chère qu’une autre. Le statut “plus sûr” de l’Australie est promu malgré le statut de virus de l’Australie ; et malgré le risque plus élevé de fausse déclaration associé à de telles différences de prix . Les différences de prix persistent en raison des efforts de marketing de longue date visant à promouvoir certaines origines et de la réglementation limitant les échanges, même entre les pays qui, selon la classification de l’OIE, présentent un statut de risque vétérinaire identique (en ce qui concerne les virus préoccupants à l’importation pour SVF). L’un des objectifs de l’ISIA est la formation des utilisateurs de sérum. L’UE et les États-Unis s’emploient à harmoniser les règles commerciales, qui contribueront toutes à harmoniser les niveaux de prix pour la plupart des origines des SVF.
FMD is relevant for regulatory import purposes but not for cell growth. The USA and a few other countries only allow FBS imports from countries free from FMD, WITHOUT vaccination while most other countries also accept FMD-free WITH vaccination. Both types of FMD-free countries are free of FMD cc and circulating FMD viruses, as verified by the OIE and declared equally safe.
Some cattle viruses can cross the placenta of the cow and infect the calf fetus, thus contaminating FBS and potentially making it unsuitable for use in cell culture. Some of these cattle viruses have a limited distribution and only exist in certain parts of the world. These are viruses of concern when importing FBS from infected countries – See Table of Diseases of Importation Concern for FBS. Other cattle viruses exist in all countries, and regardless of country of origin, the FBS must be tested or treated to assure freedom from these and other viruses (See USDA 9 CFR 113.53 and EMEA-CPMP-BWP-1793-02). The treatment of choice for most FBS is gamma irradiation at 25-45 kGy to guarantee freedom from viruses.
FBS is collected from the fetuses of pregnant cows, slaughtered in compliance with the OIE (World Animal Health Organization) guidelines and internationally accepted standards of veterinary inspection.
There is a wide range of applications for fetal bovine serum. The most important is in the field of biopharmaceuticals and vaccines. It is used in the research, manufacture and control of human and veterinary vaccines and of drugs, many of which are at the cutting edge of drug development.
Fetal bovine serum is also used extensively in research. A technique known as “Cell culture” is widely applied in the manufacture of both vaccines and bio-pharmaceuticals in which bovine serum is broadly used.
Fetal Bovine Serum (FBS) comes from the blood drawn from a bovine fetus via a closed system of collection at the slaughterhouse. Fetal Bovine serum is the most widely used serum supplement for the in vitro cell growth factors because of its high content of embryonic growth promoting factors.
The serum’s source is from a USDA Approved country. This means that serum is produced from blood collected in countries that have been approved by the United States Department of Agriculture (USDA) to export ruminant serum products to the United States. Eligible countries that export fetal bovine serum into the U.S. include: Australia, Canada, Chile, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, New Zealand, Nicaragua, and Panama.
Maintaining cells in vitro in a healthy condition and over time is a complex task. They will only survive, grow and multiply if they are well fed and provided with an appropriate and protective environment. Complex mixtures of substances (“media”) are used to bathe the cells in order to both feed and protect them. Different cells have different requirements. In many instances the presence of serum in the mixture is essential if the cells are to grow adequately and normally. Bovine serum is much the most widely used, because high quality bovine serum is available in sufficient volume and has been found to support cell growth very well indeed.
Bovine serum is a by-product of the meat industry. Bovine blood may be taken at the time of slaughter, from adult cattle, calves, very young calves or (when cows that are slaughtered are subsequently found to be pregnant) from bovine fetuses. It is also obtained from what are called “donor” animals which give blood more than once.
Blood is available from bovine fetuses only because a proportion of female animals that are slaughtered for meat for human consumption are found (often unexpectedly) to be pregnant.
Bovine serum is categorized according to the age of the animal from which the blood was collected as follows:
- Fetal bovine serum” comes from fetuses
- Newborn calf serum” comes from calves less than three weeks old
- Calf serum” comes from calves aged between three weeks and 12 months
- Adult bovine serum” comes from cattle older than 12 months
Serum is the centrifuged fluid component extracted from either clotted or defibrinated whole blood. Bovine serum comes from blood taken from domestic cattle.
Whilst the procedure of making serum may seem to be straightforward, the processing of serum takes place under very tightly controlled conditions. The process has been carefully developed and uses sophisticated facilities and equipment, and is accompanied by extensive testing particularly stringent when processed bovine serum is intended for use in the production of medicinal products.
Technical Question about FBS
Some preparations of trypsin contain phenol red. Since the product is shipped with dry ice, there could be a significant CO2 build up in packaging. This CO2 may enter the solution and lower the pH slightly, giving an orange (around pH 6.5) vs. pinkish (around 7.3) color. The solution, if orange (acidic) can still be good to use as is, or sodium hydroxide may be added to adjust the pH.
Except where notified on product labels, Biosera sera and liquid media are sterile filtered. Sterility is not guaranteed after opening. The use of aseptic manipulation techniques is recommended.
Serum is thawed at 2-8°C to prevent degradation; alternatively, it may be thawed at room temperature with periodic agitation to resuspend the contents.
Thawed serum should be mixed thoroughly before being added to cell culture medium.
Temperatures above 37°C can compromise serum performance by accelerating the degradation of critical serum factors, and should be avoided in the lab.
Turbidity and flocculent material may be present after thawing or after prolonged freezing and/or refrigeration. Our experience indicates these modifications do not affect the biological performance of the serum.
- Some deposits are due to fibrin:
Our collection procedures and rapid freezing may leave some fibrinogen in the serum. Fibrinogen is the soluble precursor of the clot-forming protein, fibrin. The fibrin may appear after thawing or heat inactivation. Fibrin does not alter the capacity of the serum to promote cell growth. It is recommended to use the serum without treatment (filtration or centrifugation).
- Some deposits are due to Calcium Phosphate:
Serum that is incubated at 37°C for extended periods will become cloudy and deposits may appear. They are composed of calcium and phosphorous. To the best of our knowledge, this does not alter the performance of the serum in cell cultures.
Serum may be stored between +2 to +8°C for up to 8 weeks without diminishing its performance (*).
Internal studies in Biowest have shown that during 26 weeks of storage (between +2 and +8°C) the serum’s capacity to promote cell growth was not significantly altered.
(*) Art to Science, Vol.19, No.2, “Serum Stability at Refrigerated Temperatures (2-8°C).
The serum should be stored frozen and protected from light. The recommended storage temperature is -10°C to -40°C. At temperatures below -40°C, the bottles may become brittle increasing the risk of breakage.
According to the OIE (World Animal Health Organization), there is no risk of BSE being transmitted in several products, including: milk, hides and skins, deboned meat, blood and blood by-products, such as fetal bovine serum (OIE Terrestrial Code 11.4 BSE). Most OIE member countries have adopted this position, including the European Union and the United States (USDA).
For some time, BSE was an argument used in favor of certain origins. After the OIE has determined that BSE is not transmitted by blood products, these arguments have become obsolete
Bovine spongiform encephalopathy (BSE), more commonly known as “mad cow” disease, is a fatal neurodegenerative disease (encephalopathy) in cattle
Biosera tests the serum for the viruses (BVD, IBR, PI3) by using a cell culture method, so that live viruses, if present, are detected in the serum.
The sampling for sterility tests of all Biowest products conforms to the European Pharmacopeia requirements.
At standard dosage of gamma irradiation, no loss of performance is observed on the first generations of cells. We notice no change on hormones, osmolarity, pH, endotoxins nor electrophoretic profile of the FBS. As ionizing radiations kill viruses, it also break some proteins and decolorate the product by reducing haemoglobin level. Radiations also decrease the serum metabolites (ALP, ALT, AST, LDH) and may slightly affect growth promotion, plating efficiency and cloning efficiency with some cell lines.
Biowest suggests you to test your cell lines with serum gamma irradiated and not in order to define the potential impact of the treatment on your applications.
If viruses seem to modify the results of your work, Biosera also propose you to test FBS Biopharm, our highest quality, certified free of 11 major cattle viruses.
FBS is sometimes gamma irradiated to eliminate all potential virus risks.
- -Start by thawing the serum and the control serum bottle at 2-8°C.
- -Stir the bottled serum to avoid a precipitant from forming during the thawing, then place it in the water bath adjusted to 80°C.
- -Once the control bottle temperature reaches 50°C, adjust the bath thermostat to 70°C; when the bottle temperature reaches 55°C, change the thermostat to 60°C.
- -When the serum reaches the temperature of 56°C, use a timer (30 minutes is the registered time) and change the thermostat of the water bath to 56°C. During those 30 minutes, check the temperature regularly and maintain it stable by adjusting the thermostat, by adding some cold water, and by lowering the lid or not. Stir the serum every 5 to 10 minutes.
- -Keep the serum at room temperature for 30 minutes, and then freeze the serum at -20°C.
The stirring is crucial for good serum quality. If the serum is not correctly mixed, a precipitant of salts, proteins and lipids will appear, and allow crystalline and flocculation deposits to form. These deposits are not toxic for cell culture but affect the serums appearance and consistency.
Heating the serum for long periods can destroy the growth promoters, which can also enable deposits to form.
For most cell culture applications, heat inactivation of serum is not recommended. Heat inactivation degrades complement proteins that may interfere with immunological assays. Heating serum for prolonged periods of time can reduce or destroy growth factors, as well as increase the formation of deposits which are commonly mistaken for microbial contamination.
- Adulteration” is the most damaging of the criminal activities that may affect serum users!
FBS can be adulterated by the addition of water, growth factors and/or serum of other species. Unscrupulous companies in order to enhance performance and/or lower the cost of the product can carry out one or more of these or similar activities. These practices are extremely serious as they affect critical results of life science research, and the purity of final products obtained in biopharmaceuticals, diagnostics, or vaccines. When such cases are detected, victims having used adulterated product must be informed to make it possible to evaluate the damage and take corrective actions.
- “Misrepresentation” is when the product is mislabeled in terms of the declared origin, and can be total or partial: “Total” is when FBS from a less expensive origin is sold as if it were from a more expensive origin; “Partial” is when a less expensive origin and a more expensive origin are mixed e.g. in proportion 49-51, and only the more expensive 51%- origin is declared. This generates an illicit profit for seller, at the expense of the serum users; and may cause companies to unknowingly violate import regulations or product master files. The actual research results and end products are unlikely to be seriously affected, but falsified origins violate government, industry and consumer standards of honesty and traceability.
- “Smuggling” is a way of misrepresentation, and can be in the form of importing a product under a false description; directly to a final destination, or via third country.
Traceability is important because it provides a chain of identity of the product from the country and slaughterhouse of origin, to the processing, packaging and labeling facilities ready for sale and final distribution. As you can verify, traceability insures that the product you buy was made respecting regulations at each level. This unbroken chain of information means complete transparency and entire compliance.